Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alberta Health services
With
The Prostate Cancer Research Foundation of Canada
Amersham Health
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
adenocarcinoma of the prostate
life expectancy \> 3 months,
symptomatic from bone metastases
radiologic evidence of metastatic bone disease
stable level of pain control
\>18 years
ability to complete assessments
prior treatment (chemo) \> 4 weeks previous
discontinued anti-androgens for \> 4 weeks
You may not be if
prior strontium therapy
previous hemibody RT within 6 weeks
previous cytotoxic chemotherapy within 4 weeks
use of bisphosphonate medications within 4 weeks
change in steroid dose within 4 weeks
active uncontrolled infection
impending or present spinal cord compression
significant neurological disorder
impending pathological fracture
severe urinary incontinence
Clareo Health | A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
